Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
8 studies found for:    TFPI2
Show Display Options
Rank Status Study
1 Completed Heparin or Enoxaparin in Patients With Cancer
Conditions: Lymphoma;   Thromboembolism;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: enoxaparin;   Drug: heparin
2 Not yet recruiting Vitamin C Infusion for Treatment in Sepsis Induced Acute Lung Injury
Conditions: Acute Lung Injury;   Sepsis
Intervention: Drug: Ascorbic Acid
3 Recruiting Study of PER977 Administered to Subjects With Steady State Edoxaban Dosing and Re-anticoagulation With Edoxaban
Condition: Healthy Volunteers
Intervention: Drug: PER977
4 Recruiting A Phase 1 Safety, Pharmacokinetics And Pharmacodynamics Study Of PF-05280602, A Recombinant Factor VIIa Variant (813d), In Adult Subjects With Hemophilia A Or B
Condition: Hemophilia A
Intervention: Biological: PF-05280602
5 Completed A Multicenter Study to Evaluate the Effects of a 91-Day Extended Cycle Oral Contraceptive on Hemostatic Parameters in Healthy Women
Conditions: Hemostasis;   Oral Contraceptive
Interventions: Drug: Levonorgestrel/ethinyl estradiol and ethinyl estradiol;   Drug: Levonorgestrel/ethinyl estradiol 0.15/0.03 mg.;   Drug: Desogestrel/ethinyl estradiol 0.15/0.03 mg
6 Completed Investigation of the Pharmacokinetics of NNC172-2021, at Two Different Dose Levels, in Healthy Japanese Subjects
Conditions: Congenital Bleeding Disorder;   Haemophilia A;   Haemophilia B;   Healthy
Interventions: Drug: NNC172-2021;   Drug: placebo
7 Completed In Vivo Evaluation of the Nipro Elisio™ Dialyzer
Condition: Chronic Kidney Disease
Interventions: Device: Elisio-210H;   Procedure: conventional hemodialysis;   Procedure: on line hemodiafiltration
8 Completed A Study to Evaluate Ovarian Follicular Activity and Hormone Levels for DR-102 Compared to Two 28-Day Oral Contraceptives
Conditions: Follicle Development;   Ovarian Follicle;   Follicle Count;   Follicle Size;   Oral Contraceptive
Interventions: Drug: Desogestrel/ethinyl estradiol and ethinyl estradiol;   Drug: 28-day drospirenone oral contraceptive;   Drug: 28-day levonorgestrel oral contraceptive

Indicates status has not been verified in more than two years